阿帕替尼联合聚乙二醇脂质体多柔比星对比聚乙二醇脂质体多柔比星单药治疗铂耐药复发性卵巢癌的疗效:APPROVE随机临床试验
APPROVE随机临床试验在中国11家医院纳入152例铂耐药复发性卵巢癌患者,比较阿帕替尼联合聚乙二醇脂质体多柔比星(PLD)与PLD单药的疗效与安全性。联合组中位无进展生存期5.8个月 vs PLD组3.3个月(HR 0.44,95%CI 0.28-0.71,P<.001),中位总生存期23.0个月 vs 14.4个月(HR 0.66,95%CI 0.40-1.09)。联合组最常见≥3级不良事件为中性粒细胞减少、高血压和白细胞减少。
要点
- 阿帕替尼联合PLD较PLD单药显著延长中位无进展生存期(5.8个月 vs 3.3个月,HR 0.44)。
- 联合组中位总生存期23.0个月 vs PLD组14.4个月,HR 0.66(95%CI 0.40-1.09)。
- 联合组≥3级不良事件以中性粒细胞减少(14.9% vs 8.3%)、高血压(8.1% vs 无)和白细胞减少(6.8% vs 4.2%)为主。
核心结论
- 阿帕替尼联合PLD在铂耐药复发性卵巢癌患者中显示出有希望的疗效和可控的毒性反应,可能成为该情境下新的替代治疗选择。
研究设计与样本
- APPROVE试验为开放标签随机临床试验,于2018年3月22日至2020年11月16日在中国11家医院开展。
- 共随机纳入152例女性患者,阿帕替尼联合PLD组78例(51.3%),PLD组74例(48.7%)。
- 纳入标准为组织学确诊的卵巢癌、在任一线铂类化疗期间或停药后6个月内出现疾病进展者。
- 主要终点为意向治疗人群按RECIST 1.1评估的无进展生存期。
主要发现
- 中位随访时间8.7个月(IQR 4.7-14.1个月)。
- 中位无进展生存期阿帕替尼联合PLD组5.8个月(95%CI 3.8-8.8)vs PLD组3.3个月(95%CI 2.1-3.8),HR 0.44(95%CI 0.28-0.71),P<.001。
- 中位总生存期阿帕替尼联合PLD组23.0个月(95%CI 18.9至未达到)vs PLD组14.4个月(95%CI 12.1-23.4),HR 0.66(95%CI 0.40-1.09)。
- 最常见的≥3级治疗中出现的不良事件:中性粒细胞计数下降阿帕替尼联合PLD组11例(14.9%)vs PLD组6例(8.3%);高血压联合组6例(8.1%)vs PLD组无;白细胞计数下降联合组5例(6.8%)vs PLD组3例(4.2%)。
- 阿帕替尼联合PLD组有2例患者发生2级瘘。
关键数值与推荐
- 阿帕替尼用法:250 mg,口服,每日一次。
- PLD用法:40 mg/m2,静脉注射,每4周一次,最多6个周期。
临床怎么用
- 作者认为,阿帕替尼联合PLD在铂耐药复发性卵巢癌患者中显示出有希望的疗效和可控的毒性反应,可能成为该情境下新的替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are substantial unmet therapeutic needs in patients with platinum-resistant recurrent ovarian cancer (PROC), and novel therapeutic strategies should be explored. OBJECTIVE: To evaluate the efficacy and safety of treatment with apatinib (a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor) plus pegylated liposomal doxorubicin (PLD) for PROC. DESIGN, SETTING, AND PARTICIPANTS: The APPROVE trial was performed as an open-label, randomized clinical trial at 11 hospitals in China between March 22, 2018, and November 16, 2020. Patients with histologically confirmed ovarian cancer who had experienced disease progression during or within 6 months of discontinuing any prior line of treatment with platinum-based chemotherapy were eligible. This primary analysis was based on data that were current as of January 28, 2021. INTERVENTIONS: Patients received PLD alone (40 mg/m2, intravenously, every 4 weeks, for up to 6 cycles) or PLD plus apatinib (250 mg, orally, daily). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, in the intent-to-treat population. RESULTS: In total, 152 female patients were randomized, with 78 (51.3%) in the apatinib plus PLD group (median age, 54 years; range, 22-76 years) and 74 (48.7%) in the PLD group (median age, 56 years; range, 33-72 years). The median follow-up duration was 8.7 months (IQR, 4.7-14.1 months). The median PFS was 5.8 months (95% CI, 3.8-8.8) for treatment with apatinib plus PLD vs 3.3 months (95% CI, 2.1-3.8) for PLD (hazard ratio, 0.44; 95% CI, 0.28-0.71; P < .001). The median overall survival was 23.0 months (95% CI, 18.9 to not reached) with treatment with apatinib plus PLD vs 14.4 months (95% CI, 12.1-23.4) with PLD (hazard ratio, 0.66; 95% CI, 0.40-1.09). The most frequent grade 3 or higher treatment-emergent adverse events were decreased neutrophil counts (11 [14.9%] in the apatinib plus PLD group vs 6 [8.3%] in the PLD group), hypertension (6 [8.1%] vs none), and decreased white blood cell count (5 [6.8%] vs 3 [4.2%]). Two patients receiving treatment with apatinib plus PLD experienced grade 2 fistulas. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that treatment with apatinib plus PLD showed promising efficacy and manageable toxic effects in patients with PROC and may be a new alternative treatment option in this setting. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT04348032.
引用
- Wang T, Tang J, Yang H, et al. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 35771546. doi:10.1001/jamaoncol.2022.2253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。